Taken together, small-molecule correctors that can interact with Tryptophan34 residue in ApoE4 and induce its proper sidechain orientation may help in modifying the aberrant conformation of ApoE4 and in turn abolish its neurotoxic and other AD-relevant downstream effects. The gene discussed is APOE; the disease is Alzheimer disease.